Table 2. Long-term survival outcomes in medically treated chronic post-embolic pulmonary hypertension patients

Treatment	Administration	First author [Ref.]	Patients n	NYHA-FC	6MWD m	Survival %
Treatment	Administration	First author [Ref.]	Patients n	NYHA-FC	6MWD m	Year 1	Year 2	Year 3	Year 5
Bosentan	Orally	Hughes [22]	47	II–IV	291±116	96	90	NA	NA
Bosentan	Orally	Seyfarth [15]	12	III	319±85	100	100	NA	NA
Epoprostenol	i.v.	Cabrol [6]	27	III–IV	265±117	73	59	41	NA
Treprostinil	Subcutaneously	Skoro-Sajer [7]	25	III–IV	260±111	80	80	80	53
Medical^#		Suntharalingam [23]	35	NA	NA	77	NA	53	NA
Medical^¶		Condliffe [20]	148	II–IV	239±133	82	NA	75	55
Medical⁺		Simonneau [21]	275	II–IV	315	88	79	70	NA

Data are presented as mean±sd, unless otherwise stated. NYHA-FC: New York Heart Association functional class; 6MWD: 6-min walking distance; NA: not available. ^#: 68% received medical treatment; ^¶: 86% received medical treatment; ⁺: 61% received medical treatment.